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Background/aim: Graves’ disease (GD) is more severe, requires a more complex treatment, and has a lower probability of achieving
remission in children than in adults. There is no consensus on the appropriate duration of antithyroid drug (ATD) treatment. Surgical
or radioactive iodine (RAI) treatments are not definitive and generally result in permanent hypothyroidism. This study’s goal was
examining the effectiveness of ATD treatment in children and adolescents with GD and determining the risk factors of remission and
relapse.
Materials and methods: This retrospective study included 45 patients (36 females and 9 males, median age 12.5 years) aged 4–18 who
were diagnosed with GD between 2003 and 2017. All patients initially were treated with an ATD. ATD treatment was discontinued at a
mean of 23.2 ± 13.2 months (10–37 months).
Results: Patients were classified into remission (n = 24) and relapse groups (n = 21). The duration of initial ATD treatment in the
remission group was longer (26.91 ± 5.17 months) than in the relapse group (19.09 ± 7.14 months) (P = 0.01). The total ATD treatment
duration was statistically longer in the remission group (42.14 ± 14.35 months) than in the relapse group (26.95 ± 16.13 months) (P =
0.03).
Conclusion: Long-term initial ATD treatment and long-term total ATD treatment were evaluated as positive parameters for the
remission of Graves’ disease in children and adolescents. Our findings showed that the chance of long-term remission increases in direct
proportion to the initial ATD treatment duration and the total ATD treatment duration.
Key words: Graves’ disease, hyperthyroidism, antithyroid drugs

1. Introduction
Graves’ disease (GD) is the most common cause of
hyperthyroidism and constitutes 10%–15% of thyroid
diseases in children. The incidence of GD is about
1/10,000 in children and adolescents (1–3). GD is more
common in girls (F/M = 5/1) and peaks in adolescence
at the age of 11–15 years (4). The diagnosis is made with
increased serum-free T3 (fT3) (2.6–4.8 pg/mL) and free
T4 (fT4) (0.7–2 ng/dL) levels, suppressed serum TSH level
(0.4–3.0 µIU/mL), positive thyroid receptor antibody
(TRab) (<1.5 IU/L), and/or the presence of exophthalmos
(4,5).
There is no consensus regarding the optimal treatment
method for GD in children and adolescents. Treatment
priorities may differ according to age (4,6). Since there
is no wide-scale, prospective, randomized study results

related to the treatment of GD in children and adolescents,
treatment of GD is generally planned individually (1).
There are medical, surgical, and radioactive iodine
(RAI) options for the treatment of GD. Each treatment
option has its own risks. In general, antithyroid drugs
(ATDs) are the first preference in the treatment of GD
(propylthiouracil (PTU), methimazole (MMI)) (7). Two
ATD regimens for medical treatment of GD have been used:
dose titration and blockage replacement. In dose titration,
the usual starting dose is 15–30 mg/day of methimazole
(or equivalent doses of other thionamides). The daily dose
is tapered down to the lowest effective dose, avoiding both
hyperthyroidism and hypothyroidism. Thyroid function
is checked every 4–6 weeks for the first 4–6 months,
then every 3–4 months until treatment is stopped after
18–24 months. In blockage-replacement, persistently
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high ATD doses are given in association with L-thyroxine
replacement to avoid hypothyroidism. Higher ATD doses
may provide a greater immunosuppressive effect for
permanent remission. Avoidance of hypothyroidism and
hyperthyroidism seems easier than with the dose-titration
method, treatment duration is shorter, and fewer visits are
required. However, the much higher number of tablets
taken every day may create compliance problems and may
have a higher risk of side effects (8).
Long-term use of ATDs may lead to the development
of side effects and adaptation problems (7,9). The mortality
rate is approximately 25%–50% after the development
of PTU-related hepatoxicity. Another study showed
that severe liver damage occurred in 22 patients treated
with PTU, resulting in high rates of mortality (death in
9 cases, liver transplantation in 5 cases). In 2009, the US
Food and Drug Administration (FDA) recommended
that PTU should not be used to treat GD in children
and adolescents (10–13). MMI treatment is available as
an alternative treatment since it has comparatively fewer
side effects. Limitations in medical treatment (toxicity,
relapse, adaptation problems, treatment duration) place
RAI or surgical treatment at the forefront (4,6,7). RAI and
surgical treatments, however, bear risks in terms of timing
of the procedure, age of the patient, and some potential
complications such as hypothyroidism.
Studies that investigate the predictive factors for relapse
or remission and the requirement for radical treatments
at an early stage are limited. The course of GD varies
individually, as do the factors associated with remission
and relapse. Patients who are older, have a higher body
mass index, smaller goiters, lower thyroid hormone levels
at diagnosis, and negative TRab can achieve remission
in the early period. It has been shown that prepubertal
children can achieve remission for a longer period than
pubertal and postpubertal children. The risk of relapse
increases in patients whose TRab levels are higher. Patients
whose hyperthyroidism was corrected within 4–6 months
with ATD treatment achieved long-term remission.
Management of patients with GD will be easier if patients
can be identified as requiring long-term ATD treatment
or requiring radical treatment (RAI or surgery) through
reliable indicators for relapse and remission in the early
period (14,15).
The objective of this study was to evaluate the clinical
features and to determine the predictive factors related to
relapse and remission in children and adolescents with
GD.
2. Materials and methods
This retrospective study included 45 subjects with GD who
were aged 4–18. The patients were followed for at least 1
year between 2003 and 2017 at the Pediatric Endocrinology

Department of Behçet Uz Children’s Hospital. The study
was approved by the Behçet Uz Children’s Hospital’s
Ethical Council with ethical council number: 2016 / 0301, folder number: 2016/61.
The following parameters were recorded for each
patient at the time of admission: age at diagnosis, sex,
body weight, weight standard deviation score (SDS),
height SDS, body mass index SDS, pulse rate, systolic
and diastolic blood pressure (above the 95th percentile
was accepted as hypertension for the norms determined
for age and sex (16)), clinical goiter and ophthalmopathy,
puberty state according to Tanner staging (17,18), and
family history of autoimmune thyroid disease. Free T3, free
T4, fT3/fT4 ratio, TRab, antithyroid peroxidase antibody
(anti-TPO) (0–9 IU/mL), and antithyroglobulin antibody
(anti-TG) (0–4 IU/mL) were recorded at the onset of
diagnosis. High transaminase level was considered when
alanine aminotransferase (ALT) (0–35 U/L) and aspartate
aminotransferase (AST) (0–35 U/L) were twice the normal
values, and leukopenia was considered when the leukocyte
count was below 4500/µL (16). Thyroid volume, thyroid
parenchyma echogenicity, pseudonodular appearance,
and blood flow rate evaluated via thyroid ultrasonography
were recorded. Thyroid gland volume and volume SDS
were calculated using ÇEDD Çözüm software (TPEDS
Metrics) (19,20).
GD was diagnosed with increased fT3 and fT4 levels,
suppressed TSH level, and/or positive TRab (2,21,22). The
patients were monitored both clinically and with laboratory
testing for 3–6 months. Starting dose, duration of use, side
effects of the antithyroid drugs (MMI, PTU, propranolol),
and periods of normalization of fT4 and TRab levels
were recorded. The patients who had received RAI or
surgical treatment (total or subtotal thyroidectomy) were
registered. The final states of the cases were classified as
hypothyroidism, euthyroidism, and currently undergoing
ATD treatment.
Remission was defined as the sustainment of a clinical
and biochemical state of euthyroidism for at least 1
year following the termination of ATD treatment and
no relapse in follow-up (23,24). Relapse was defined as
increased fT4 or fT3 levels in addition to suppressed serum
TSH level following dose reduction or termination of
ATDs in patients who receive at least 12 months of proper
treatment (2). The cases were classified into the groups
“relapse” and “remission.”
2.1. Statistical analysis
SPSS 24.0 for Windows was used for statistical analysis.
Descriptive statistics, number and percentage for
categorical variables, and average ± standard deviation
for data that meet the normal distribution parameters
for numeric variables have been provided. Student’s t-test
was applied for continuous variables (age at diagnosis;
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anthropometric measurements; mean initial fT4, fT3, and
fT3/fT4 ratio; initial thyroid US volume; fT4 normalization
time; TRab normalization time; initial ATD treatment
duration; and total duration of ATD Rx) during the
comparison of 2 independent groups, while the chi-square
test was used for categorical variables (sex; family history
of AITD (n); puberty (n); Graves’ ophthalmopathy (n);
initial positive TRab (n); initial positive anti-TPO (n);
initial positive anti-TG (n); the number of patients who
initially received MMI, PTU, and Na-L-thyroxine; and
positive TRab at the end of ATD Rx (n)). P < 0.05 was
accepted as significant.
3. Results
Of the 45 patients included in the study, 36 (80%) were
female and 9 (20%) were male. Their median age at
diagnosis was 12.5 years (range: 4–18 years). Thirtytwo (71%) were in the pubertal stage. Family history of
autoimmune thyroid disease was present in 32 (72%)
cases. Ophthalmopathy was determined in 11 (24%) of
the cases. Systolic blood pressure, defined as above the
95th percentile according to sex and height, was detected
in 4 (13%) out of 30 patients whose blood pressure (BP)
was measured. Body weight SDS and BMI SDS of these
patients were within normal limits. The mean weight SDS
was –0.10 ± 0.9 and the mean BMI SDS was 0.40 ± 0.89.
Thyroid gland size was observed in physical examination
to be increased above average for age and sex in 38 patients
(85%). The mean thyroid volume and the mean thyroid
volume SDS calculated via thyroid ultrasonography were
14.8 ± 8.6 mL and 7.86 ± 6.61 mL. Mean fT4 level was 3.96
± 1.67 ng/dL, mean fT3 level was 14.46 ± 5.94 pg/mL, and

mean fT3/fT4 ratio was 3.65 ± 0.72 at the time of diagnosis.
At the onset of diagnosis, TRab was measured in 38
patients. TRab was detected positive in 26 (68%) patients
and was detected negative in the remaining 12 patients (9
relapse, 3 remission). In these 12 patients and in 7 patients
whose TRab was not measured at the time of diagnosis,
TRab was detected positive in the follow-up period. For
this reason, hashitoxicosis was not considered. Anti-TPO
and anti-TG levels were positive in 24 (63%) cases. TRab,
anti-TPO, and anti-TG were positive in 14 (31%) of cases.
TRab was detected positive only in 6 (13%) cases. Of the
12 cases with negative TRab levels, positive anti-TPO
and/or anti-TG levels were detected in 7 (16%). Initially,
ATD treatment was started for all patients diagnosed with
GD. Twenty-two of the patients were treated with MMI
(mean starting dose: 0.65 ± 0.24 mg/kg/day), and 23 of the
patients were treated with PTU (mean starting dose: 3.88
± 1.37 mg/kg/day). Following the FDA recommendation
in 2009, PTU treatment was discontinued in 5 patients
and MMI therapy was started instead. Initially propranolol
(mean starting dose: 1.50 ± 0.46 mg/kg/day) was started in
36 patients (80%) because of tachycardia. Dose-titration
treatment was used in 9 (20%) of the cases, and blockagereplacement treatment was used in 36 (80%) of the cases.
ATD treatment was stopped for patients with normal or
close to normal TRab levels as well as those who remained
in euthyroid state for at least 12 months with low doses of
ATD (MMI 2.5–5 mg/day or PTU 25–50 mg/day). ATD
treatment was discontinued at the end of a mean treatment
period of 23.2 ± 13.2 months (10–73 months) in all cases.
Figure 1 shows the clinical course of the cases. Remission
was achieved by 24 (53%) patients during follow-up.

Diagnosis of GD &
started ATD Rx
n= 45

Remission
n= 24

RAI
n= 2

Relapse
n= 21

Remission
n= 5

Case of
Hypothyroidism
n= 2

Figure 1. Clinical course of cases.
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Relapse occurred in 21 (47%) cases. Of the 21 cases of
relapse, 2 of these patients received RAI treatment and 4
underwent surgical treatment (three subtotal and one total
thyroidectomy). ATD treatment was restarted in these
remaining 15 patients. Of these 15 patients, 10 (22%) are
still undergoing ATD treatment and 5 went into remission
during follow-up. In the long term, 32 patients achieved
euthyroidism (71%), hypothyroidism developed in 3
cases (1 case after total thyroidectomy, 2 cases after RAI),
and 10 (22%) patients were still under ATD treatment
(Figure 1). There was no statistically significant difference
between remission and relapse groups according to age at
diagnosis, weight SDS, height SDS, and BMI SDS (Table).
Thyroid function tests and thyroid volume of the relapse
group were determined to be similar in comparison with

the remission group (P = 0.142). The time until TRab
reached a normal level was not statistically significant even
though there was an increase in the relapse group (28.8 ±
11 months) compared to the remission group (22.3 ± 13.02
months) (P = 0.267). The period of total ATD treatment
was higher in the remission group (42.14 ± 14.35 months)
in comparison with the relapse group (26.9 ± 16.1 months)
(P = 0.03). The duration of initial ATD treatment was
statistically higher in the remission group than in the
relapse group (respectively 26.9 ± 5.17 months and 19.09 ±
7.14 months, P = 0.01). Figure 2 shows the distribution of
the initial ATD treatment duration in the remission group.
Figure 3 shows the distribution of the total ATD treatment
duration in the remission group. Dose-titration treatment
was administered in 3 cases in the remission group and 6

Table. Clinical and biochemical characteristics of remission and relapse groups. Student’s t-test and chi-square
test were used for statistical analysis.
Remission (n = 24)

Relapse (n = 21)

P

Age at diagnosis (years)

10.96 ± 3.24

12.01 ± 3.22

0.246

Sex (F/M)

18/6

18/3

0.370

Weight SDS at diagnosis

0.01 ± 0.87

–0.24 ± 1.03

0.375

Height SDS at diagnosis

0.39 ± 1

0.42 ± 0.77

0.911

BMI SDS at diagnosis

–0.38 ± 1.08

–0.31 ± 1.22

0.839

Family history of AITD (n)

15

17

0.173

Puberty (n)

15

17

0.173

Graves’ ophthalmopathy (n)

7

4

0.431

Initial fT4 (0.7–2 ng/dL)

3.66 ± 1.69

4.20 ± 1.73

0.302

Initial fT3 (2.6–4.8 pg/mL)

13.32 ± 6.64

14.86 ± 5.61

0.410

Initial fT3/fT4 ratio

3.66 ± 0.76

3.63 ± 0.70

0.892

Initial positive TRab (n)

10

16

0.064

Initial positive anti-TPO (n)

8

16

0.060

Initial positive anti-TG (n)

12

12

0.580

Initial thyroid US volume (mL)

16.46 ± 6.62

12.82 ± 9.98

0.142

Initial

PTU (n)

16

7

0.080

MMI (n)

8

14

0.186

21

15

0.179

Na- L-thyroxine (n)
Positive TRab at end of ATD Rx (n)

2

3

0.602

fT4 normalization time (weeks)

6.45 ± 3.89

6.85 ± 4.36

0.731

TRab normalization time (months)

22.28 ± 13.02

28.85 ± 11.00

0.267

Initial ATD treatment duration (months)

26.91 ± 5,17

0.01

Total ATD treatment duration (months)

42.14 ± 14.35

19.09 ± 7.14
26.95 ± 16.13

0.03

AITD: Autoimmune thyroid disease, BMI: body mass index, SDS: standard deviation scores, TRab: thyrotropin
receptor antibody, TPO: thyroid peroxidase, TG: thyroglobulin, US: ultrasonography, ATD: antithyroid drug,
fT4: free thyroxine, fT3: free triiodothyronine, PTU: propylthiouracil, MMI: methimazole, RAI: radioactive
iodine.

467

40
35
30
25
20
15
10
5
0

60
50
40
Month

Month

TUNÇ et al. / Turk J Med Sci

20
10

0

5

10

15
Patients

20

25

30

Figure 2. Initial ATD treatment duration in the remission group.

cases in the relapse group. Blockage-replacement treatment
was used in 21 cases in the remission group and 15 cases
in the relapse group. There was no significant difference
between dose-titration method and blockage-replacement
method with regard to remission and relapse development
(P = 0.179).
Side effects due to ATD treatment were observed in
2 cases (4.4%). One patient had elevated transaminase
levels, while the other had an allergic skin rash. Both were
receiving PTU at that time. PTU treatment was changed to
MMI because of side effects. The mean age at diagnosis of
patients who developed side effects was 12.5 ± 3.5 years.
4. Discussion
Long-term remission is observed at lower rates for GD in
children in compared to adults. While the remission rate
in children and adolescents in response to ATD treatment
varies from 29% to 49%, the rate is between 39.5% and 85%
in adults. Ohye et al. (25) reported that the remission rate
was 46.2% and the relapse rate was 34.2% in children and
adolescents. Remission and relapse rates were determined
to be 53.4% and 46% in our study.
The onset of GD is thought to depend on complex
interactions among multiple genetic, environmental, and
endogenous factors. For this reason, the factors associated
with remission and relapse may also vary from individual
to individual. Many retrospective and prospective studies
have studied factors predicting remission and relapse for
children with GD. However, no stable predicting factors
have been determined. Glaser et al. (14) showed that a high
BMI score and smaller goiter size at the onset of diagnosis
were predictors for remission, while Mussa et al. (26)
showed that low TRab levels at the time of diagnosis and
throughout the ATD treatment were related to remission.
Similarly, Graser et al. (27) reported that a low sT3 level
at the time of diagnosis and normalization of the thyroid
functions within the first 3 months were affirmative
predictors for remission. Kaguelidou et al. (28) found that
relapse predictors were a younger age at diagnosis, severity
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Figure 3. Total ATD treatment duration in remission group.

of the disease at the onset of diagnosis, and ethnicity (being
non-Caucasian). Ohye et al. (25) could not determine a
statistically significant risk factor for remission or relapse.
There were differences in sample size, analysis methods,
and parameters measured among these studies. Those
differences may have been responsible for the variety
of the factors predicting remission and relapse. In this
study, the initial ATD treatment duration and total ATD
treatment duration parameters were statistically proved to
be predictors of long-term remission. Other parameters
were not found to be valuable as predictors of remission
or relapse. Previous studies have shown that the clinical
course is milder in patients who have TRab negativity at
onset of the disease and small goiter size (29). In our study,
the rate at which TRab became negative at the end of ATD
treatment was similar between the remission and relapse
groups (P = 0.602).
There is no consensus on the optimal ATD treatment
duration to provide long-term remission of GD in
children and adolescents. There is no sufficient evidence
with regard to increasing the chance of remission in GD
when using ATDs for more than 1 or 2 years in children
and adolescents (30). It has been found that the remission
rate after about 2 years of ATD treatment is lower than
30%, together with a high relapse rate (2,7,13). However,
Léger et al. (7) noted that a total 2-year ATD treatment
in children was associated with a cumulative increase in
the remission rate. Ohye et al. (25) reported a correlation
between cumulative remission rate and the duration of
treatment in 334 of 639 children and adolescents with
GD. In our study initial ATD treatment duration and
total ATD treatment duration were determined to be
statistically longer in the remission group in comparison
with the relapse group (P = 0.01, P = 0.03, respectively).
Immune dysregulation induced by hyperthyroidism can
be reinstated with euthyroidism. Therefore, chance of
permanent remission of patients may be increased by
staying in the euthyroid state for a long period (31). It is
important when treating patients for a long duration to use
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the lowest possible ATD dose so as to increase the chance
of remission and minimize the risk of side effects (32–34).
There are studies suggesting that remission in GD with
ATD treatment is independent of the type of drug (MMI
or PTU) (28). Remission is independent of the additional
use of levothyroxine. Propranolol, which is administered
to alleviate the symptoms of hyperthyroidism, does not
decrease the secretion of thyroid hormone and has no
immunosuppressive effect. However, Codaccioni et al.
(35) found long-term remission in 8 out of 26 (30.7%)
patients treated only with propranolol. This rate is close
to the spontaneous remission ratio expected (31%) in
GD (36). This condition is explained by researchers as a
spontaneous remission seen in the natural course of GD,
as in other autoimmune diseases, and propranolol does not
have a direct impact on remission. There were no patients
treated with only propranolol in our study. Propranolol was
administered in addition to ATD treatment in 35 (78%)
patients. We did not detect a significant difference in terms
of achieving remission in patients receiving propranolol.
TSH receptor antibody positivity is important for
diagnosis and follow-up of GD. It is commonly used as
an assisted laboratory test in diagnosis of GD. A decrease
in TRab level is expected due to reduced activity of the
disease when in remission, and it is expected to increase in
relapse based on increased disease activity (37). Contrary
to what would be expected, TRab may not be positive at
the onset of diagnosis, and TRab may become negative
at the end of ATD treatment (35,38). In our study, TRab
was negative for 9 patients at the onset of diagnosis, and
2 positive TRab values switched to negative at the end
of ATD treatment in the relapse group. This discrepancy
may be explained by the opinion that the TRab levels in
circulation may not reflect the intrathyroidal TRab level,
as discussed previously in the literature (35,38).
The medical treatment of GD may be carried out
by dose-titration treatment or blockage-replacement
treatment. It can be expected that a higher ATD dose will
result in a higher rate of side effects. Since greater doses
of ATD are required in blockage-replacement, evidence
acquired from adults supports the opinion that dosetitration is the superior method (39). It is also a matter
of debate whether blockage-replacement provides more
remission in comparison with ATD treatment alone.
It has been indicated in many studies that remission is
independent of the dose of levothyroxine included in
blockage-replacement (31,40). It has also been suggested
that blockage-replacement decreases the frequency
of follow-up required and provides longer periods of
euthyroidism (8,38).
While 9 patients in our study received dose-titration
treatment, 36 patients received blockage-replacement
treatment. Remission and relapse rates were similar
between these groups.

It has been reported that the rate of side effects due to
ATD usage in GD is lower in children (5.1%–3%) than
in adults (13.9%–51.9%) (41). In our study, the observed
side effects were a skin rash (1 case) and an increase in
liver function (1 case) (4.4%). Both patients were receiving
PTU at the time. Even though no side effects from MMI
treatment were observed in this study, patients treated
with MMI should be carefully monitored for side effects
such as liver dysfunction, skin reactions, and neutropenia.
Radical treatment methods (RAI or surgery) should
be taken into consideration in children when medical
treatment has failed. Deciding to switch to definitive
treatment requires not only taking into account the
various prognostic factors that have been identified, but
also considering the balance between individual risks and
benefits based on the patient’s background and clinical
course. It has been emphasized in a metaanalysis of adults
that the optimal ATD treatment duration for GD is 12–
18 months. If no remission is observed after this period,
radical treatment options should be considered (39). The
American Thyroid Association suggests radical treatment
options for children in cases where remission cannot be
attained following 2 years of ATD treatment (42). However,
higher rates of remission are more probable with long
periods of ATD treatment in children than adults (43), so
radical treatment options should not be considered right
away, even if recovery cannot be attained after 2 years of
ATD treatment. We also determined that the length of
total ATD treatment duration (42.14 ± 14.35 months)
was a significant determining factor for remission. In our
study, the average length of ATD treatment prior to usage
of radical treatment was 3.5 years.
The most important problem that is observed in
patients who receive radical treatment is the failure to
adapt to long-term Na-L-thyroxine treatment. In addition,
thyroidectomy has a higher complication rate in children
than in adults. Haddow et al. revealed that 10 (30%) out
of 33 patients treated with RAI experienced adaptation
problems in long-term replacement treatment. These
problems are an especially serious issue for women in the
fertile period of their lives (44). In our study, 3 (2 surgery,
1 RAI) out of 6 patients whose received radical treatment
continue to receive replacement treatment with Na-Lthyroxine. Therefore, remission should be attempted to
be achieved with ATD prior to trying radical treatment.
Families should be informed that ATD treatment may be
long-lasting and that treatment with Na-L-thyroxine may
be required for the remainder of the patient’s life in cases
in which RAI or surgical treatment are received (40).
In conclusion, ATD treatment is effective and reliable
at achieving long-term remission of GD in children and
adolescents. Because of this, children and adolescents with
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GD should be treated with long-term ATD before radical
treatment. Radical treatment (RAI and surgery) should be
considered as the last option and only in selected cases.
In children and adolescents, the chance of long-term

remission increases in proportion with the initial ATD
treatment duration and the total ATD treatment duration.
There is a need for further prospective randomized studies
to evaluate the optimal treatment duration.
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